Celebrex

Celebrex
Name	Celecoxib
Trade names	Celebrex
Atc	M01AH01
Legal status	Prescription only
Routes of administration	Oral
Bioavailability	~40%
Protein bound	97%
Metabolism	Hepatic (CYP2C9)
Elimination half-life	8–12 hours
Excretion	Feces and urine

Celebrex

Celebrex is a prescription nonsteroidal anti-inflammatory drug primarily used for relief of pain and inflammation. It was developed for conditions involving chronic pain and inflammatory processes and is often prescribed by specialists in rheumatology, orthopaedics, and pain medicine. The molecule is associated with contemporary debates in pharmacovigilance and health policy due to cardiovascular safety assessments.

Medical uses

Celebrex is indicated for symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute pain management after surgical procedures. It is also approved for management of primary dysmenorrhea and for familial adenomatous polyposis as an adjunct to surgical intervention in select patients. Prescribers in clinical practice often consider Celebrex for patients requiring long-term anti-inflammatory therapy when gastrointestinal risk with traditional nonselective agents is concern; the choice parallels guidance from specialist societies and comparative studies including randomized controlled trials and systematic reviews from organizations involved in musculoskeletal care.

Pharmacology

Celebrex selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis implicated in inflammation and nociception. Its selectivity differentiates it from nonselective COX inhibitors and relates to molecular interactions characterized in medicinal chemistry and enzymology literature. Metabolism occurs in the liver predominantly via cytochrome P450 2C9 with subsequent renal and biliary excretion; pharmacokinetics vary with age, hepatic function and genetic polymorphisms studied in pharmacogenetics. Pharmacodynamic effects include analgesia, anti-inflammatory action and antipyresis, with implications studied in perioperative medicine and chronic disease management.

Dosage and administration

Dosing regimens for Celebrex vary by indication and patient factors; common adult dosages include once or twice daily schedules tailored for osteoarthritis, rheumatoid arthritis, acute pain and dysmenorrhea. Clinicians adjust dose for older adults and those with hepatic impairment while avoiding use in severe hepatic dysfunction. Tablets are administered orally with or without food; therapeutic monitoring relies on clinical response and adverse event surveillance often coordinated between primary care, rheumatology and pharmacy services.

Side effects and safety

Common adverse events include gastrointestinal symptoms, headache, upper respiratory infections and edema. Serious risks associated with COX-2 selective inhibition—highlighted in postmarketing surveillance and cardiovascular outcome studies—include increased risk of myocardial infarction, stroke and thrombotic events in certain populations. Renal adverse effects such as acute kidney injury and electrolyte disturbances have been reported, particularly in patients with compromised renal perfusion. Safety considerations are addressed in clinical guidelines, cardiology consensus statements and pharmacovigilance reports.

Contraindications and interactions

Celebrex is contraindicated in patients with known hypersensitivity to sulfonamides or previous aspirin-exacerbated respiratory disease and in those with established coronary artery bypass graft surgery for perioperative pain. Potential drug interactions occur with anticoagulants (increasing bleeding risk), diuretics and renin–angiotensin system agents (altering renal function), and CYP2C9 substrates or inhibitors (modifying plasma concentrations). Clinical decisions often reference drug interaction compendia, cardiology recommendations and hepatology guidance when co-prescribing with agents metabolized by hepatic enzymes.

History and development

The compound was discovered and developed in the late 20th century amid efforts in pharmaceutical chemistry to create COX-2 selective inhibitors. Its development involved collaboration among research divisions within major pharmaceutical companies and academic groups in medicinal chemistry and pharmacology. Early clinical trials, regulatory submissions and large-scale postmarketing studies influenced contemporary understanding of COX-2 selectivity, safety profiles and subsequent development of related agents. Historical discussions appear in analyses of drug safety controversies, litigation archives and health policy reviews.

Regulatory status and availability

Celebrex is approved for prescription use in many jurisdictions and its regulatory status has evolved following safety reviews by national agencies. Market availability is subject to national formularies, reimbursement policies and patent lifecycles that impacted generic entry and pricing dynamics. Accessibility in clinical settings is managed by hospitals, pharmacies and outpatient clinics under prescription control, and ongoing regulatory communications address labeling updates informed by post-authorization safety data.

Category:Nonsteroidal anti-inflammatory drugs